Compare ClearPoint Neuro Inc (CLPT) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Paychex, Inc. — how do they compare? ClearPoint Neuro Inc trades at $15.85 (market cap $478.63M), while Paychex, Inc. trades at $111.85 (market cap $38.95B). The key difference: Paychex, Inc. is far larger — about 81.4× ClearPoint Neuro Inc's market cap, and Paychex, Inc. pays a 4.35% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | PAYX | |
|---|---|---|
Market Cap | $478.63M | $38.95B |
Sector | Health | Industrials |
52-Week High | $29.60 | $147.99 |
52-Week Low | $8.66 | $85.57 |
Enterprise Value | $506.63M | $42.43B |
Dividend Yield | — | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Paychex (PAYX) trades at $110.75, up 2.98% with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.32 beating expectations, and maintains robust profitability with 27.03% net income margin. Recent dividend payment of $1.19 and positive business momentum from AI expansion and small business hiring trends support growth outlook.
Outlook remains positive with steady revenue growth and AI-driven efficiency gains, though valuation multiples appear elevated with P/E of 22.65. Risks include competitive pressures and macroeconomic sensitivity to small business employment trends. Analyst consensus is mixed with 16.67% buy ratings but price target alignment with current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
